

SUPPLEMENTARY MATERIAL

A. Specification of contact balance (CB)

1. Matrix of CB according to the longitudinal position (longitudinal CB): symmetric (blue square) and asymmetric (yellow diamond); posterior (post, gray case) and non-posterior (non-post, white case).

position	ant	in-between	interant	in-between	interpost	in-between	post
ant	□	□	□	◊	◊	◊	◊
in-between	□	□	□	□	□	◊	◊
interant	□	□	□	□	□	◊	◊
in-between	□	□	□	□	□	□	□
interpost	◊	□	□	□	□	□	□
in-between	◊	◊	□	□	□	□	□
post	◊	◊	◊	◊	□	□	□

2. Matrix of CB according to the transversal position (transversal CB): symmetric (blue circle) and asymmetric (yellow triangle); superolateral (gray case) and non-superolateral (white case).

position	in-between	suplat	in-between	supmed	in-between	infmed	in-between	inflat
in-between	○	○	△	△	△	△	△	○
suplat	○	○	○	△	△	△	△	△
in-between	△	○	○	○	△	△	△	△
supmed	△	△	○	○	○	△	△	△
in-between	△	△	△	○	○	○	△	△
infmed	△	△	△	△	○	○	○	△
in-between	△	△	△	△	△	○	○	○
inflat	○	△	△	△	△	△	○	○

B. Table of patient CB. Baseline and 1 year characteristics of patients according to patient CB (sym-p, asym-p; n, collected data out of 92; values \pm standard error); p values of differences (significant, bold italic) between settings (Δ pat_CB); 1 year versus baseline (Δ P#postpre); dopa effect, at baseline and 1 year, and baseline_dopa effect – 1 year_dopa-effect ^(a); at 1 year, stim effect and dopa effect – stim effect ^(b).

characteristics	baseline						1 year							
	sym-p		asym-p		Δ pat_CB		sym-p		asym-p		Δ pat_CB			
	mean \pm SD	n	mean \pm SD	n	p value	mean \pm SD	n	mean \pm SD	n	p value	Δ P#postpre	Δ #sym-p	Δ #asym-p	
age (y)	61.0206 \pm 6.9763	64	60.4951 \pm 6.6883	28	0.659									
gender (female)	28	64	14	28	0.371									
disease duration (y; quartile)	10.3968 \pm 3.5855	63	10.6071 \pm 4.3575	28	0.8329									
LED (mg)	1280.79 \pm 473.8679	62	1104.5 \pm 482.4856	25	0.1622									
stimulation voltage (V)	left													
	right													
	n.a.													
Hoehn & Yahr score	on-period	1.7627 \pm 0.8776	59	1.8541 \pm 0.9146	24	0.9534	2.0784\pm0.8023	51	2.2727 \pm 0.6310	22	0.4560	0.8447	0.0118 (47)	0.0580 (19)
	off-period	2.2704 \pm 0.7335	61	2.6 \pm 0.75	25	0.1562	2.4909 \pm 0.9102	55	2.5681 \pm 0.7447	22	0.6777	0.4337	0.1363 (52)	0.7389 (21)
ADLs (UPDRS II)	on-period	4.7719 \pm 4.2521	57	4.4565 \pm 3.4703	23	0.9234	10\pm5.7560	50	9.305\pm1.1669	20	0.8656	0.7979	<0.0001 (48)	<0.0001 (20)
	off-period	16.3620 \pm 5.4304	58	16.3695 \pm 6.0456	23	0.8461	15.8265 \pm 6.8210	49	16.35 \pm 6.4910	20	0.7156	0.4629	0.4583 (47)	0.6268 (20)
UPDRS II-5 speech	on-period	0.4126 \pm 0.7542	63	0.5357 \pm 0.7444	28	0.3274	1.4649\pm1.1013	57	1.5208\pm1.0982	24	0.8144	0.8446	<0.0001 (56)	0.0001 (24)
	off-period	1.0476 \pm 0.9743	63	1.2962 \pm 0.9120	27	0.2155	1.8392\pm1.0184	56	1.7708\pm1.0630	24	0.7152	0.4315	<0.0001 (55)	0.0328 (23)
UPDRS II-14 stamping	on-period	0.1810 \pm 0.4654	58	0.2 \pm 0.5	25	0.9311	0.5\pm0.7549	51	0.3636\pm0.7895	22	0.2836	0.4290	0.0006 (49)	0.0457 (49)
	off-period	1.0862 \pm 1.1740	58	0.92 \pm 0.256	25	0.4056	1.02 \pm 1.0349	50	1.2043 \pm 1.2785	22	0.7152	0.4342	0.8285 (48)	0.2100 (21)
UPDRS IV-dyskinesia	A32 (%)	1.7177 \pm 1.0187	62	1.8571 \pm 1.0440	28	0.4487	0.2807\pm0.7008	57	0.0833\pm0.2823	24	0.2058	0.4586	<0.0001 (55)	<0.0001 (24)
UPDRS IV-fluctuations	A33 (disability)	1.7983 \pm 1.1923	62	1.3928 \pm 0.9164	28	0.0656	0.1578\pm0.5602	57	0.0833\pm0.2823	24	0.2098	0.0483	<0.0001 (55)	<0.0001 (24)
	B39 (% off)	1.6031 \pm 0.7304	63	1.5892 \pm 0.5279	28	0.7052	1.0701\pm0.6508	57	1\pm0.6593	24	0.6087	0.5857	0.0002 (56)	0.0022 (24)
PDQ-39	mobility 1–10	19.021 \pm 8.6035	47	16.1666 \pm 9.1588	24	0.2189	15.2 \pm 8.1486	35	16.75 \pm 10.1315	12	0.9028	0.3317	0.1353 (29)	0.9645 (11)
	activities of daily living 11–16	10.0638 \pm 4.8651	47	9.2608 \pm 4.3507	23	0.5723	7.2355 \pm 3.6850	34	8.5384 \pm 5.5470	13	0.5193	0.3807	0.0646 (28)	0.8932 (11)
	emotional well-being 17–22	8.8098 \pm 4.9742	42	9.5 \pm 0.615	22	0.8261	7.3437\pm4.1510	32	7.8333 \pm 4.9512	12	0.7607	0.9842	0.0325 (23)	0.2396 (10)
	stigma-depression 23–26	6.1521 \pm 3.5211	46	6.7083 \pm 3.4068	24	0.5259	3.9142\pm3.3427	35	5.2307 \pm 3.3703	10	0.2029	0.5338	0.0154 (28)	0.3653 (12)
	social support 27–29	2.0227 \pm 2.4730	44	3.2380 \pm 2.9984	21	0.1401	1.7419 \pm 2.1903	31	2.1818 \pm 2.4007	11	0.5319	0.3598	0.6013 (27)	0.2540 (9)
	cognition 30–33	5.2127\pm2.5532	47	4.625\pm2.8408	24	0.0130	4.8055\pm2.4473	36	2.7692\pm2.3149	13	0.0147	0.5308	0.4352 (29)	0.2153 (12)
	communication 34–36	3.1363 \pm 2.1630	44	4.0869 \pm 2.0430	23	0.1006	4.6111\pm2.4293	36	3.3076 \pm 2.6890	13	0.1438	0.0354	0.0097 (27)	0.5367 (12)
	bodyly discomfort 37–39	5.8181 \pm 2.7132	44	5.6521 \pm 3.4851	23	0.9363	4.7714\pm2.5905	35	4.3846 \pm 3.5009	13	0.6651	0.6788	0.0104 (27)	0.0575 (12)
UPDRS III total	DOPA-OFF	30.2578 \pm 10.8492	64	35.1481 \pm 11.7790	27	0.0894								
	DOPA-ON	9.5873 \pm 5.5529	63	9.6428 \pm 6.2743	28	0.8938								
	dopa effect	69.111 \pm 11.7564	63	72.4511 \pm 13.9569	27	0.1500								
	DOPA-OFF STIM-OFF						36.8125\pm14.7189	64	40.76\pm10.6600	25	0.1012	0.5148	<0.0001 (64)	0.0223 (24)
	DOPA-ON STIM-OFF						15\pm9.7277	40	16.625\pm10.2865	20	0.6434	0.4092	<0.0001 (39)	0.0008 (20)
	dopa effect (%) ^a						58.6987\pm18.1604	40	61.1078\pm19.6862	20	0.6663	0.9274	0.0009 (39)	0.0196 (19)
	DOPA-OFF STIM-ON						22.8015 \pm 11.4994	63	24.6 \pm 8.2701	25	0.2569		n.a.	
	stim effect (%) ^b						38.1385\pm17.259	63	39.1034\pm15.6238	25	0.4906	0.7657	<0.0001 (40)	0.0019 (20)
	DOPA-ON STIM-ON						14.2372 \pm 8.5794	59	14.6521 \pm 7.2359	23	0.7100		n.a.	
	overall effect (%)						61.6504 \pm 14.5691	59	64.1182 \pm 14.7928	23	0.6312			
III-18 speech	DOPA-OFF	0.8281 \pm 0.6797	64	0.7142 \pm 0.6586	28	0.4738								
	DOPA-ON	0.5238 \pm 0.6685	63	0.4821 \pm 0.5689	28	0.9650								
	dopa effect	40.5303 \pm 52.0134	44	26.4705 \pm 53.3785	17	0.4058								
	DOPA-OFF STIM-OFF						1.2656\pm0.8862	64	1.5\pm0.8485	26	0.2688	0.1478	0.0003 (64)	0.0001 (26)
	DOPA-ON STIM-OFF						1.0731\pm0.7463	41	1.4\pm1.0462	20	0.3088	0.2400	<0.0001 (40)	0.0003 (20)
	dopa effect (%) ^a						10.4166\pm38.1296	36	9.2592 \pm 41.4098	18	0.8262	0.8042	0.0302 (23)	0.1127 (11)
	DOPA-OFF STIM-ON						1.3281 \pm 0.9310	64	1.6548 \pm 0.9139	26	0.1116		n.a.	
	stim effect (%) ^b						-2.2435\pm38.0672	52	-13.1944\pm31.7482	24	0.1074	0.2242	0.0334 (36)	0.0410 (18)
	DOPA-ON STIM-ON						1.254 \pm 0.8875	59	1.6666 \pm 0.8805	24	0.0647		n.a.	
	overall effect (%)						6.6666 \pm 40.2303	50	35.7142 \pm 42.5851	21	0.5786			
III-28 posture	DOPA-OFF	1.4062 \pm 0.9589	64	1.3214 \pm 0.8629	28	0.7272								
	DOPA-ON	0.7777 \pm 0.7058	63	0.6964 \pm 0.8315	28	0.4701								
	dopa effect	43.8580 \pm 40.6496	54	53.125 \pm 47.0643	24	0.3935								
	DOPA-OFF STIM-OFF						1.4921 \pm 0.9150	64	1.5576 \pm 1.1164	26	0.9480	0.3530	0.6341 (64)	0.1668 (26)
	DOPA-ON STIM-OFF						0.9878\pm0.9778	41	1.025\pm1.0572	20	0.9934	0.2427	0.1932 (40)	0.0117 (20)
	dopa effect (%) ^a						30.9803 \pm 40.4064	34	35.1851 \pm 44.6075	18	0.8309	0.4628	0.3719 (28)	0.0962 (17)
	DOPA-OFF STIM-ON						1.375 \pm 0.9385	64	1.4423 \pm 1.0800	26	0.9931		n.a.	
	stim effect (%) ^b						9.6060\pm25.2985	55	6.006\pm15.8910	22	0.7409	0.3973	0.0016 (34)	0.0086 (18)
	DOPA-ON STIM-ON						1.0677 \pm 0.9212	59	0.9791 \pm 0.9833	24	0.5689		n.a.	
	overall effect (%)						28.9 \pm 37.8228	50	35.7142 \pm 42.5851	21	0.5786			
III-29 postural stability	DOPA-OFF	0.6953 \pm 0.7216	64	1.0178 \pm 1.0044	28	0.1481								
	DOPA-ON	0.3571 \pm 0.5034	63	0.3214 \pm 0.4557	28	0.8176								
	dopa effect	47.5877 \pm 51.0736	38	71.25 \pm 37.8009	20	0.0926								
	DOPA-OFF STIM-OFF						1.1562\pm1.0034	64	1.0384\pm0.8593	26	0.6709	0.0408	0.0002 (64)	0.8716 (26)
	DOPA-ON STIM-OFF						0.5\pm0.6020	41	0.75\pm0.8350	20	0.3231	0.0407	0.3758 (40)	0.0088 (20)
	dopa effect (%) ^a						51.3440\pm43.2529	31	45.3703\pm47.0730	18	0.5976	0.0321	0.1583 (2)	0.0810 (14)
	DOPA-OFF STIM-ON						0.8828 \pm 0.7854	64	0.8076 \pm 0.7358	26	0.7228		n.a.	
	stim effect (%) ^b						22.0486$\pm</math$							

C. **Table of longitudinal CB.** Baseline and 1 year characteristics of patients according to longitudinal CB (sym-post, sym-non-post, asym-L; n, collected data out of 92; values \pm standard error, SD); p values of differences (significant, bold italic) between settings (Δ long_CB); 1 year versus baseline (Δ L#postpre); dopa effect, at baseline and 1 year, and baseline_dopa effect – 1 year_dopa-effect^(a); at 1 year, stim effect and dopa effect – stim effect^(b).

characteristics	baseline										1 year																																		
	sym-post					sym-non-post					asym-L					sym-post					sym-non-post					asym-L					long_CB					Ulipostpre					sym-post				
	mean ± SD	n	mean ± SD	n	p value	mean ± SD	n	mean ± SD	n	p value	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n	mean ± SD	n									
age (y)	61.105±6.5495	47	60.145±7.1086	39	0.59	50.031±7.8818	6	0.440																																					
gender (female)	20	47	20	39	0.672	2	6	0.672																																					
disease duration (y; quartile)	10.965±3.9268	46	9.719±3.4864	39	11.5±8.002	6	5.080																																						
EDL (mg)	1231.006±114.7564	46	1236.392±54.4028	36	1171.5±600.2168	5	0.804																																						
stimulation voltage (V)	left		n.a.																																										
	right		n.a.																																										
Hoech & Yahr score	on period	1.7045±0.8715	44	1.8428±0.9375	35	2.25±0.2886	4	0.4623																																					
	off-period	2.3444±0.7820	45	2.4077±0.7542	35	2.3±0.4472	5	0.8229																																					
ADLs (UPDRS II)	on period	4.4909±3.3062	45	5.2149±4.8800	36	3.6±2.0736	5	0.8812																																					
	off-period	16.6±5.2046	45	16.3044±6.4488	31	14.62±6.076	5	0.7497																																					
UPDRS II speech	on period	0.0442±0.1119	47	0.5263±0.7065	38	0.3333±0.8164	6	0.6177																																					
	off-period	1.0869±0.9147	46	1.1842±1.0359	38	1±0.8944	6	0.9154																																					
UPDRS II-4 stamping	on period	0.2±0.4572	45	0.1099±0.2944	33	0±0	5	0.5917																																					
	off-period	1.1677±1.007	45	1.0909±1.2399	33	1±1.4142	5	0.9390																																					
UPDRS II-4 stamping	on period	2.0±0.4572	45	0.1099±0.2944	33	0±0	5	0.5917																																					
UPDRS IV-dyskinesia	A32 (%)	1.6131±1.0255	46	1.8947±1.0600	38	1.8333±0.7527	6	0.4019																																					
ADLs (A33) (disability)	A32 (%)	1.6521±1.1395	46	1.236±1.1894	35	1.5±0.5477	6	0.7762																																					
UPDRS IV-fluctuations	B39 (wtf)	1.6080±0.6949	47	1.5657±0.6593	31	1.1666±0.4082	6	0.1710																																					
mobility 1-10	activities or daily living 1-10	18.351±9.5225	37	18.172±0.8309	29	13.2±8.1363	5	0.4371																																					
	emotional well-being 17-22	10.8010±5.1713	37	9.8725±4.0006	29	7.4±3.804	5	0.4372																																					
PDQ-39	staging dependence 2-26	9.5806±5.4819	31	7.925±4.5373	28	9.6±3.5637	5	0.3475																																					
	cognition 20-33	2.5±2.7516	36	2.3±2.5740	25	2.7±2.5217	5	0.8517																																					
UPDRS III total	communication 34-36	3.75±2.3099	36	2.92±0.1980	26	4.2±1.631	5	0.2075																																					
	bodily discomfort 37-39	5.8883±1.3421	36	5.52±0.8879	26	6.2±2.5884	5	0.8276																																					
UPDRS OFF	DOPA-OFF	30.1847±9.8484	46	36.3310±13.2724	39	30.8333±5.6803	6	0.5071																																					
	DOPA-ON	9.3152±5.0098	46	10.2948±6.0965	36	7.3333±3.089	6	0.5243																																					
UPDRS OFF-STIM-OFF	DOPA-OFF	69.6240±12.8535	45	69.6383±11.9499	39	75.9394±13.4235	6	0.3979																																					
	DOPA-ON																																												
UPDRS III total	DOPA-OFF STIM-OFF	0.7872±0.6895	47	0.8974±0.6405	39	0.1666±0.4082	6	0.0368																																					
	DOPA-ON	0.4782±0.6232	46	0.5769±0.6338	39	0.3333±0.8164	6	0.4195																																					
	dopamine	41.6666±47.4947	30	36.1111±52.3551	30	-100.n.a.	1	0.1768																																					
III-18 speech	DOPA-OFF STIM-OFF	0.7872±0.6895	47	0.8974±0.6405	39	0.1666±0.4082	6	0.0368																																					
	DOPA-ON																																												
III-18 speech	DOPA-OFF STIM-OFF	0.7872±0.6895	47	0.8974±0.6405	39	0.1666±0.4082	6	0.0368																																					
	DOPA-ON																																												
III-28 posture	DOPA-OFF STIM-OFF	1.4148±0.9573	47	1.4230±0.9566	39	0.8333±0.4082	6	0.2688																																					
	DOPA-ON	0.7826±0.8144	46	0.7826±0.6766	39	0.3333±0.5163	6	0.3302																																					
	dopamine	47.0923±42.3723	39	53.6274±42.9967	34	60.51±7.7722	5	0.7347																																					
III-29 posture stability	DOPA-OFF STIM-OFF	0.7872±0.6895	47	0.8974±0.6405	39	0.1666±0.4082	6	0.0368																																					
	DOPA-ON																																												
III-29 posture stability	DOPA-OFF STIM-OFF	0.7872±0.6895	47	0.8974±0.6405	39	0.1666±0.4082	6	0.0368																																					
	DOPA-ON																																												
III-30 walk	DOPA-OFF STIM-OFF	0.7872±0.6895	47	0.8974±0.6405	39	0.1666±0.4082	6	0.0368																																					
	DOPA-ON																																												
III-30 walk	DOPA-OFF STIM-OFF	0.7872±0.6895	47	0.8974±0.6405	39	0.1666±0.4082	6	0.0368																																					
	DOPA-ON																																												
III-30 walk	DOPA-OFF STIM-OFF	0.7872±0.6895	47	0.8974±0.6405	39	0.1666±0.4082	6	0.0368																																					
	DOPA-ON																																												
III-30 walk	DOPA-OFF STIM-OFF	0.7872±0.6895	47	0.8974±0.6405	39	0.1666±0.4082	6	0.0368				</																																	

D. **Table of transversal CB.** Baseline and 1 year characteristics of patients according to transversal CB (sym-suplat, sym-non-suplat, asym-T; n, collected data out of 92; values \pm standard error, SD); p values of differences (significant, bold italic) between settings (Δ trans_CB); 1 year versus baseline (Δ T#postpre); dopa effect, at baseline and 1 year, and baseline_dopa effect – 1 year_dopa effect ^(a); at 1 year, stim effect and dopa effect – stim effect ^(b).

E. **Table of STN relation CB.** Baseline and 1 year characteristics of patients according to STN relation CB (sym-out, sym-non-out, asym-N; n, collected data out of 92; values \pm standard error, SD); p values of differences (significant, bold italic) between settings (Δ STN_CB); 1 year versus baseline (Δ STN#postpre); dopa effect, at baseline and 1 year, and baseline_dopa effect – 1 year_dopa effect ^(a); at 1 year, stim effect and dopa effect – stim effect ^(b).

F. Baseline, 1-year and variation of clinical characteristics (general F1, speech F2, and gait F3) according to patient CB and sub-aspects, longitudinal and transversal positions, and STN relation (see text for details): ■ no significant variation; □ worsening; ▨ improvement (less than ▨); ■ stim effect < dopa effect; — not relevant; ○ not accessible to statistical analysis; baseline_dopa effect – 1-year_dopa effect (a); at 1-year, stim effect and dopa effect – stim effect (b).

F1

characteristics	patient CB						longitudinal CB						transversal CB						STN relation CB							
	baseline		1 year		variation		baseline		1 year		variation		baseline		1 year		variation		baseline		1 year		variation			
	sym	asym	sym	asym	sym	asym		sym	asym	sym	asym			sym	asym	sym	asym			sym	asym	sym	asym			
age	■	—	—	—	—	—	■	—	—	—	—	—	■	—	—	—	—	—	■	—	—	—	—	—	—	
gender	—	—	—	—	—	—	■	—	—	—	—	—	■	—	—	—	—	—	■	—	—	—	—	—	—	
disease duration	■	■	■	■	■	■	■	■	■	■	■	○	■	■	■	■	■	■	■	■	■	○	■	■	■	
LED	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
stimulation voltage	left	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	
Hoehn & Yahr score	on-period	■	■	■	■	■	■	■	■	■	■	○	■	■	■	■	■	■	■	■	■	■	○	■	■	■
ADLs (UPDRS II)	on-period	■	■	■	■	■	■	■	■	■	■	○	■	■	■	■	■	■	■	■	■	■	○	■	■	■
UPDRS IV-dyskinesia	A32 (%)	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
UPDRS IV-fluctuations	B39 (% off)	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
PDQ39	mobility 1–10	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	activities of daily living 11–16	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	emotional well-being 17–22	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	stigma 23–26	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	social support 27–29	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	cognition 30–33	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	communication 34–36	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	body discomfort 37–39	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-OFF	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-ON	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	dopa effect	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-OFF STIM-OFF	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-ON STIM-OFF	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	dopa effect (a)	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-OFF STIM-ON	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	stim effect (b)	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-ON STIM-ON	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	overall effect	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■

F2

characteristics	patient CB						longitudinal CB						transversal CB						STN relation CB						
	baseline		1 year		variation		baseline		1 year		variation		baseline		1 year		variation		baseline		1 year		variation		
	sym	asym	sym	asym	sym	asym		sym	asym	sym	asym			sym	asym	sym	asym			sym	asym	sym	asym		
UPDRS II-5 speech	on-period	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	off-period	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-OFF	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-ON	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	dopa effect	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-OFF STIM-OFF	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-ON STIM-OFF	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	dopa effect (a)	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-OFF STIM-ON	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	stim effect (b)	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-ON STIM-ON	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	overall effect	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■

F3

characteristics	patient CB						longitudinal CB						transversal CB						STN relation CB						
	baseline		1 year		variation		baseline		1 year		variation		baseline		1 year		variation		baseline		1 year		variation		
	sym	asym	sym	asym	sym	asym		sym	asym	sym	asym			sym	asym	sym	asym			sym	asym	sym	asym		
UPDRS II-14 freezing	on-period	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	off-period	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-OFF	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■	■
	DOPA-ON	■	■	■</																					